Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹37 Cr.
Stock P/E
-346.9
P/B
3.9
Current Price
₹120
Book Value
₹ 30.9
Face Value
10
52W High
₹120
52W Low
₹ 0
Dividend Yield
0%

Chemiesynth (Vapi) Overview

Business

Chemiesynth (Vapi) Ltd. is an Indian chemical company primarily engaged in the manufacturing and synthesis of various chemical products. As implied by its name, it likely specializes in chemical synthesis processes. The company operates on a B2B model, supplying its chemical products as intermediates or specialty chemicals to a range of industries such as pharmaceuticals, agrochemicals, dyes, pigments, or other industrial applications. Its core business model involves leveraging its manufacturing capabilities and chemical expertise to produce and sell these compounds, generating revenue from direct sales to industrial customers.

Revenue Mix

Specific key segments and their revenue contributions are not publicly available from the given information. Typically, a chemical synthesis company like Chemiesynth might have segments focused on:

Specialty Chemicals: High-value, low-volume chemicals for specific applications.

Pharmaceutical Intermediates: Chemicals used in the synthesis of active pharmaceutical ingredients (APIs).

Agrochemical Intermediates: Chemicals used in the production of pesticides, herbicides, and fungicides.

Basic Chemicals / Dyes & Pigments Intermediates: More commoditized chemicals or inputs for colorant industries.

Without detailed product portfolio information, a precise breakdown is not possible.

Industry

Chemiesynth operates in the Indian Chemicals sector, a vast and diverse industry comprising basic chemicals, specialty chemicals, agrochemicals, petrochemicals, and pharmaceuticals. The Indian chemical industry is characterized by a mix of large integrated players and numerous small to mid-sized companies. It is highly competitive, with both domestic and international participants. Chemiesynth, likely a mid-cap or small-cap player, would compete on factors such as cost-efficiency, product quality, regulatory compliance, and potentially specialized product offerings. Its positioning likely caters to specific niches or offers contract manufacturing services within the broader chemical supply chain.

MOAT

Without specific details, any competitive advantages are inferred:

Cost Efficiency: Potential for a moat through economies of scale, efficient manufacturing processes, or access to low-cost raw materials.

Process Know-how: Specialized expertise in complex chemical synthesis processes, leading to better yields or unique products.

Customer Relationships: Long-standing relationships with key industrial clients, leading to sticky demand.

Regulatory Compliance & Location: Adherence to stringent environmental and safety regulations (especially critical in Vapi, a significant industrial zone) can act as a barrier to entry for new players.

A strong, durable moat based on brand or network effects is less typical for a B2B chemical synthesis company unless it holds proprietary technology or dominant market share in a critical niche.

Growth Drivers

"China Plus One" Strategy: Global companies diversifying their chemical supply chains away from China, benefiting Indian manufacturers.

Domestic Demand Growth: Expanding end-user industries in India (pharmaceuticals, agrochemicals, consumer goods, automotive) driving demand for chemicals.

Import Substitution: Government initiatives promoting local manufacturing ("Make in India") to reduce reliance on imports.

Capacity Expansion: Investment in new production facilities or debottlenecking existing ones to meet growing demand.

New Product Development: Expanding product portfolio into higher-margin specialty chemicals or new application areas through R&D.

Risks

Raw Material Price Volatility: Fluctuations in the prices of key chemical intermediates and energy inputs can impact profitability.

Environmental & Regulatory Risks: Stringent environmental norms and compliance costs, potential for operational disruptions due to regulatory actions.

Intense Competition: Competition from both domestic and international players can put pressure on pricing and margins.

Economic Downturn: A slowdown in end-user industries (e.g., pharma, auto) can reduce demand for its products.

Technological Obsolescence: Failure to adopt newer, more efficient, or environmentally friendly manufacturing processes.

Foreign Exchange Fluctuations: If the company has significant import dependencies or export revenues.

Management & Ownership

As a listed Indian company, Chemiesynth (Vapi) Ltd. likely has a promoter group holding a significant stake, typical for many Indian businesses. The management team would be responsible for day-to-day operations and strategic direction. Details regarding the specific promoters, their background, or the quality of management are not available in the provided information and would require further investigation into public filings and corporate governance reports. Ownership structure would include the promoter group, institutional investors, and public shareholders.

Outlook

Chemiesynth operates within the dynamic Indian chemical sector, which enjoys several tailwinds, including robust domestic demand, government support for manufacturing, and global supply chain diversification. This provides a favorable environment for growth. The company's ability to capitalize on these opportunities will depend on its operational efficiency, capacity utilization, strategic product portfolio expansion into higher-value specialty chemicals, and strong customer relationships. However, it faces inherent risks such as raw material price volatility, stringent regulatory scrutiny, and intense competition. Its long-term success will hinge on disciplined capital allocation, continuous innovation, and adept management of both market opportunities and operational challenges.

Chemiesynth (Vapi) Share Price

Live · BSE · Inception: 1986
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Chemiesynth (Vapi) Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 4 3 5 4 7 4 7 5 6 4
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 4 3 5 4 7 4 7 5 6 4
Total Expenditure 4 3 5 4 6 4 7 5 4 4
Operating Profit 0 0 1 0 1 0 0 -0 1 0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -0 -0 0 -0 0 -0 -0 -1 1 -1
Provision for Tax -0 0 0 0 0 0 0 0 -0 0
Profit After Tax -0 -0 0 -0 0 -0 -0 -1 1 -1
Adjustments 0 0 0 0 0 0 -0 0 0 -0
Profit After Adjustments -0 -0 0 -0 0 -0 -0 -1 1 -1
Adjusted Earnings Per Share -0.7 -0.8 1.4 -1.5 0.6 -1.5 -1.4 -2.3 2 -1.9

Chemiesynth (Vapi) Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 11 5 3 13 11 15 20 30 21 16 19 22
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Income 11 5 3 14 11 15 20 30 21 16 19 22
Total Expenditure 12 5 3 13 9 12 14 26 18 15 17 20
Operating Profit -0 -0 0 1 2 2 6 4 3 2 2 1
Interest 0 0 0 0 0 0 0 0 1 1 1 0
Depreciation 0 0 0 1 0 1 1 1 1 1 1 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 1 0 0 0 0
Profit Before Tax -1 -1 -0 0 1 2 4 4 1 -0 -0 -1
Provision for Tax 0 0 0 0 0 0 1 1 0 -0 0 0
Profit After Tax -1 -1 -0 0 1 1 4 3 1 -0 -0 -1
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -1 -1 -0 0 1 1 4 3 1 -0 -0 -1
Adjusted Earnings Per Share -3.2 -1.8 -0.6 1.3 3.8 4.3 11.6 8.8 1.8 -1.3 -0.3 -3.6

Chemiesynth (Vapi) Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 3 2 2 2 4 5 8 11 12 11 11
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 6 7 7 7 7 7 9 8 8 9 8
Other Non-Current Liabilities 1 1 0 0 0 0 0 1 1 1 1
Total Current Liabilities 3 2 2 2 4 6 9 10 10 10 12
Total Liabilities 12 12 12 12 15 18 27 30 31 31 32
Fixed Assets 10 10 10 10 11 12 20 22 25 25 26
Other Non-Current Assets 0 0 0 0 1 2 0 1 1 1 1
Total Current Assets 2 1 2 2 4 4 6 7 6 5 6
Total Assets 12 12 12 12 15 18 27 30 31 31 32

Chemiesynth (Vapi) Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 1 0 0 1 0 0
Cash Flow from Operating Activities -0 -2 -0 1 3 1 6 3 0 -0 3
Cash Flow from Investing Activities 0 -0 0 -0 -2 -3 -8 -3 -3 -2 -2
Cash Flow from Financing Activities -0 2 -0 -0 -0 2 1 1 2 2 -1
Net Cash Inflow / Outflow -0 -0 0 0 0 -0 0 1 -1 0 -0
Closing Cash & Cash Equivalent 0 0 0 0 1 0 0 1 0 0 0

Chemiesynth (Vapi) Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0 0 0 0 0 11.6 8.85 1.81 -1.26 -0.35
CEPS(Rs) -2.25 -1.11 -0 2.98 5.31 6.05 14.14 12.28 5.61 2.97 4.22
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0 0 0 0 0 0 27.55 36.39 38.2 36.94 35.77
Core EBITDA Margin(%) -3.8 -2.71 -2.55 4.85 17.33 15.71 28.03 14.82 12.27 9.41 11.7
EBIT Margin(%) -6.14 -6.16 0.35 4.35 13.76 12.73 24.2 14.43 6.72 1.56 4.33
Pre Tax Margin(%) -8.72 -10.62 -5.86 2.96 13 10.84 21.79 12.79 3.89 -2.74 -0.04
PAT Margin (%) -8.72 -10.62 -5.86 2.96 10.48 8.97 17.9 9 2.65 -2.36 -0.56
Cash Profit Margin (%) -6.19 -6.68 -0 6.88 14.56 12.74 21.82 12.49 8.22 5.55 6.87
ROA(%) -7.63 -4.55 -1.55 3.35 8.68 7.94 15.94 9.62 1.83 -1.24 -0.33
ROE(%) -31.04 -22.95 -8.8 17.79 39.1 30.81 53.35 27.67 4.85 -3.37 -0.95
ROCE(%) -7.04 -3.22 0.11 5.67 14.21 14.32 28.37 20.7 5.85 0.98 3.1
Receivable days 18.83 44.88 38.35 16.43 43.75 41.08 48.47 43.18 53.61 53.63 48.04
Inventory Days 40.01 50.24 95.72 18.3 25.6 37.58 29.55 21.77 44.16 68.63 50.7
Payable days 124.37 305.85 595.16 49.61 394.56 375.49 523.77 192.13 248.4 227.94 141.26
PER(x) 0 0 0 0 0 0 0 2.05 11.05 0 0
Price/Book(x) 0 0 0 0 0 0 0 0.5 0.52 0.73 0
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.87 2.18 3.55 0.82 0.91 0.86 0.68 0.54 0.94 1.44 0.96
EV/Core EBITDA(x) -24.08 -98.13 57.14 9.95 5.12 5.2 2.42 3.6 7.68 15.24 8.13
Net Sales Growth(%) 15.58 -54.01 -39.59 330.49 -15.88 30.03 36.62 51.69 -30.62 -21.52 14.93
EBIT Growth(%) -263.51 53.8 103.42 5275.76 165.96 20.29 159.65 -9.56 -67.69 -81.77 219.14
PAT Growth(%) -947.66 43.98 66.67 317.7 197.48 11.35 172.54 -23.74 -79.55 -169.87 72.65
EPS Growth(%) 0 0 0 0 0 0 172.53 -23.74 -79.55 -169.87 72.65
Debt/Equity(x) 2.54 3.89 3.97 3.32 2.14 1.99 1.28 1.04 1.16 1.37 1.37
Current Ratio(x) 0.54 0.7 0.67 0.9 0.91 0.64 0.65 0.68 0.61 0.54 0.47
Quick Ratio(x) 0.31 0.38 0.26 0.73 0.63 0.34 0.5 0.46 0.3 0.21 0.3
Interest Cover(x) -2.38 -1.38 0.06 3.13 18 6.71 10.02 8.79 2.37 0.36 0.99
Total Debt/Mcap(x) 0 0 0 0 0 0 0 2.08 2.22 1.89 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +19% -14% +5% +6%
Operating Profit CAGR 0% -21% 0% —
PAT CAGR — -100% -100% —
Share Price CAGR +219% +85% — —
ROE Average -1% 0% +16% +10%
ROCE Average +3% +3% +12% +8%

Chemiesynth (Vapi) Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 62.35 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 37.65 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 62.3562.3562.3562.3562.3562.3562.3562.3562.3562.35
FII 0000000000
DII 0000000000
Public 37.6537.6537.6537.6537.6537.6537.6537.6537.6537.65
Others 0000000000
Total 100100100100100100100100100100

Chemiesynth (Vapi) Peer Comparison

Chemicals Edit Columns

Chemiesynth (Vapi) Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Chemiesynth (Vapi) Pros & Cons

Pros

  • Debtor days have improved from 227.94 to 141.26days.
  • Company has reduced debt.

Cons

  • Company has a low return on equity of 0% over the last 3 years.
  • Stock is trading at 3.9 times its book value.
  • The company has delivered a poor profit growth of -100% over past five years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp